Match!
Thomas K. Oliver
American Society of Clinical Oncology
CancerPathologyRandomized controlled trialGuidelineMedicine
45Publications
22H-index
2,354Citations
What is this?
Publications 46
Newest
#1Manish A. Shah (Cornell University)H-Index: 49
#2Thomas K. Oliver (American Society of Clinical Oncology)H-Index: 22
Last. Mariana Chavez-MacGregor (University of Texas MD Anderson Cancer Center)H-Index: 25
view all 7 authors...
ASCO engages in the endorsement and adaptation of clinical practice guidelines to recognize the high-quality work of other guideline-developing organizations, to avoid duplication of effort, and to...
Source
#1Paul Celano (Greater Baltimore Medical Center)H-Index: 6
#2Christopher A. Fausel (Indiana University Health)H-Index: 1
Last. Robin ZonH-Index: 13
view all 8 authors...
PURPOSETo provide 2019 ASCO standards on the safe handling of hazardous drugs.METHODSAn Expert Panel was formed, and a systematic review of the literature on closed system transfer devices was performed to May 2017 using PubMed. The Cochrane Database of Systematic Reviews, PubMed, and Google Scholar were used to search for studies of medical surveillance and external ventilation/health effects of exposure to vapors to November 2017. Available standards were considered for endorsement. Public com...
Source
#1Paul Celano (Greater Baltimore Medical Center)H-Index: 6
#2Erin B. Kennedy (American Society of Clinical Oncology)H-Index: 10
Last. Robin ZonH-Index: 13
view all 4 authors...
Source
#1Sana Al-SukhunH-Index: 1
#2Sarah Temin (American Society of Clinical Oncology)H-Index: 23
Last. Julie R. Gralow (UW: University of Washington)H-Index: 63
view all 8 authors...
The objectives of this article are to describe the ASCO Resource-Stratified Guidelines and to provide background within the context of ASCO Guidelines and efforts to address the global cancer burden.
1 CitationsSource
#1Jason D. Merker (Stanford University)H-Index: 19
#2Geoffrey R. Oxnard (Harvard University)H-Index: 38
Last. Nicholas C. TurnerH-Index: 45
view all 17 authors...
PurposeClinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research.MethodsAn Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and u...
131 CitationsSource
#1Nasser HannaH-Index: 36
#2Sarah Temin (American Society of Clinical Oncology)H-Index: 23
Last. Gregory A. Masters (Christiana Care Health System)H-Index: 18
view all 4 authors...
Source
#1Katherine S. Virgo (Emory University)H-Index: 42
#2Ethan Basch (UNC: University of North Carolina at Chapel Hill)H-Index: 57
Last. Eric A. Singer (RU: Rutgers University)H-Index: 21
view all 10 authors...
PurposeASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naive men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but minimal symptoms.Clinical ContextThe treatment goal for CRPC is palliation. Despite resistance to initial an...
16 CitationsSource
#1Mark R. Somerfield (American Society of Clinical Oncology)H-Index: 57
#2Kari Bohlke (American Society of Clinical Oncology)H-Index: 10
Last. Gary H. Lyman (UW: University of Washington)H-Index: 89
view all 12 authors...
Since the beginning of its guidelines program in 1993, ASCO has continually sought ways to produce a greater number of guidelines while maintaining its commitment to using the rigorous development methods that minimize the biases that threaten the validity of practice recommendations. ASCO is implementing a range of guideline development and implementation innovations. In this article, we describe innovations that are designed to (1) integrate consideration of multiple chronic conditions into pr...
7 CitationsSource
#1Ethan Basch (UNC: University of North Carolina at Chapel Hill)H-Index: 57
#2D. Andrew Loblaw (Sunnybrook Health Sciences Centre)H-Index: 9
Last. Katherine S. Virgo (Emory University)H-Index: 42
view all 20 authors...
Purpose To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC).
129 CitationsSource
#1Michael Fung-Kee-Fung (U of O: University of Ottawa)H-Index: 19
#2Thomas K. Oliver (McMaster University)H-Index: 22
In Canada, approximately 4,400 women are diagnosed with endometrial cancer each year and approximately 800 die from the disease [1]. The majority of patients present with early-stage disease and this is reflected in an overall 5-year survival rate of approximately 85 % [1]. Five-year survival rates range from approximately 96 % for patients with local disease, 66 % for those with regional disease, and 25 % for those with more advanced disease [2]. Factors predictive of recurrence and survival in...
Source
12345